{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T21:51:35Z","timestamp":1781646695499,"version":"3.54.5"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T00:00:00Z","timestamp":1774483200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T00:00:00Z","timestamp":1777939200000},"content-version":"vor","delay-in-days":40,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["NCI R37CA227865-01A1"],"award-info":[{"award-number":["NCI R37CA227865-01A1"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["NCI R37CA278982"],"award-info":[{"award-number":["NCI R37CA278982"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["NCI R37CA227865-01A1"],"award-info":[{"award-number":["NCI R37CA227865-01A1"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"name":"K12 Case Western Reserve University"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Exp Clin Cancer Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Malignant melanoma is one of the most common types of cancer in the United States. Despite improvements in therapeutics, advanced disease is often lethal if the cancer develops resistance to immune and targeted therapies. Metabolic reprogramming is an important hallmark of cancer and drives resistance to certain therapies. Previous efforts to modulate melanoma metabolism have focused on targeting glycolysis, whereas targeting mitochondrial oxidative phosphorylation (OXPHOS) and the TCA cycle is relatively less developed for melanoma.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Melanoma cell lines were evaluated under chemotherapy-associated stress using assays of mitochondrial function and oxidative metabolism. Pharmacologic inhibition of the mitochondrial electron transport chain was assessed using complex I inhibitors in combination with conventional anti-melanoma chemotherapy in preclinical in vitro models, with validation in animal models.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Melanoma cells rely heavily on mitochondrial function, particularly under chemotherapy-associated stress, as evidenced by increased OXPHOS activity. Pharmacologic inhibition of the mitochondrial electron transport chain (ETC) with complex I inhibitors (Phenformin and IACS-010759) synergizes with conventional anti-melanoma chemotherapy in pre-clinical in vitro models of melanoma, with added benefit in animal models.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>These findings suggest that melanoma adapts to chemotherapy by increasing mitochondrial oxidative metabolism. Targeting the ETC offers a compelling strategy to enhance chemotherapy activity in patients with advanced and treatment-refractory melanoma.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13046-026-03685-8","type":"journal-article","created":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T00:03:06Z","timestamp":1774483386000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Melanoma resists chemotherapy through an adaptive mitochondrial response"],"prefix":"10.1186","volume":"45","author":[{"given":"Mehrdad","family":"Zarei","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Semmer A.","family":"Ali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander W.","family":"Loftus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faith","family":"Nakazzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hallie J.","family":"Graor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Om","family":"Prajapati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sami O.","family":"Abul-Khoudoud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John M.","family":"Asara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordan M.","family":"Winter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luke D.","family":"Rothermel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,26]]},"reference":[{"key":"3685_CR1","doi-asserted-by":"crossref","unstructured":"Wolchok JD, Chiarion-Sileni V, Gonzalez R, Grob J-J, Rutkowski P, Lao CD, et al. CheckMate 067: 6.5-year outcomes in patients with advanced melanoma. Journal of Clinical Oncology. 2021;39 Suppl 15:9506.","DOI":"10.1200\/JCO.2021.39.15_suppl.9506"},{"key":"3685_CR2","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1056\/NEJMra041245","volume":"351","author":"H Tsao","year":"2004","unstructured":"Tsao H, Atkins MB, Sober AJ. Management of cutaneous melanoma. N Engl J Med Mass Med Soc. 2004;351:998\u20131012.","journal-title":"N Engl J Med Mass Med Soc"},{"key":"3685_CR3","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1056\/NEJMoa1910836","volume":"381","author":"J Larkin","year":"2019","unstructured":"Larkin J, Chiarion-Sileni V, Gonzalez R, Grob J-J, Rutkowski P, Lao CD, et al. Five-year survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med Mass Med Soc. 2019;381:1535\u201346.","journal-title":"N Engl J Med Mass Med Soc"},{"key":"3685_CR4","first-page":"e2426641","volume":"7","author":"OJ van Not","year":"2024","unstructured":"van Not OJ, van den Eertwegh AJM, Jalving H, Bloem M, Haanen JB, van Rijn RS, et al. Long-term survival in patients with advanced melanoma. JAMA Netw open Am Med Association. 2024;7:e2426641\u20132426641.","journal-title":"JAMA Netw open Am Med Association"},{"key":"3685_CR5","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa2407417","volume":"392","author":"JD Wolchok","year":"2025","unstructured":"Wolchok JD, Chiarion-Sileni V, Rutkowski P, Cowey CL, Schadendorf D, Wagstaff J, et al. Final, 10-year outcomes with nivolumab plus ipilimumab in advanced melanoma. N Engl J Med Mass Med Soc. 2025;392:11\u201322.","journal-title":"N Engl J Med Mass Med Soc"},{"key":"3685_CR6","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1056\/NEJMoa1504030","volume":"373","author":"J Larkin","year":"2015","unstructured":"Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med Mass Med Soc. 2015;373:23\u201334.","journal-title":"N Engl J Med Mass Med Soc"},{"key":"3685_CR7","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1158\/1078-0432.CCR-17-2267","volume":"24","author":"TN Gide","year":"2018","unstructured":"Gide TN, Wilmott JS, Scolyer RA, Long GV. Primary and acquired resistance to immune checkpoint inhibitors in metastatic melanoma. Clin Cancer Res AACR. 2018;24:1260\u201370.","journal-title":"Clin Cancer Res AACR"},{"key":"3685_CR8","first-page":"48","volume-title":"Combination therapy with BRAF and MEK inhibitors for melanoma: latest evidence and place in therapy. Ther Adv Med Oncol","author":"Z Eroglu","year":"2016","unstructured":"Eroglu Z, Ribas A. Combination therapy with BRAF and MEK inhibitors for melanoma: latest evidence and place in therapy. Ther Adv Med Oncol. Volume 8. London, England: SAGE Publications Sage UK; 2016. pp. 48\u201356."},{"key":"3685_CR9","doi-asserted-by":"publisher","first-page":"1877","DOI":"10.1056\/NEJMoa1406037","volume":"371","author":"GV Long","year":"2014","unstructured":"Long GV, Stroyakovskiy D, Gogas H, Levchenko E, de Braud F, Larkin J, et al. Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. N Engl J Med Mass Med Soc. 2014;371:1877\u201388.","journal-title":"N Engl J Med Mass Med Soc"},{"key":"3685_CR10","doi-asserted-by":"publisher","first-page":"102795","DOI":"10.1016\/j.ctrv.2024.102795","volume":"129","author":"AW Loftus","year":"2024","unstructured":"Loftus AW, Zarei M, Kakish H, Hajihassani O, Hue JJ, Boutros C, et al. Therapeutic implications of the metabolic changes associated with BRAF inhibition in melanoma. Cancer Treat Rev Elsevier. 2024;129:102795.","journal-title":"Cancer Treat Rev Elsevier"},{"key":"3685_CR11","doi-asserted-by":"publisher","first-page":"1867","DOI":"10.1056\/NEJMoa1408868","volume":"371","author":"J Larkin","year":"2014","unstructured":"Larkin J, Ascierto PA, Dr\u00e9no B, Atkinson V, Liszkay G, Maio M, et al. Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. N Engl J Med Mass Med Soc. 2014;371:1867\u201376.","journal-title":"N Engl J Med Mass Med Soc"},{"key":"3685_CR12","first-page":"5184","volume":"14","author":"HH Kakish","year":"2022","unstructured":"Kakish HH, Ahmed FA, Elshami M, Loftus AW, Hoehn RS, Ammori JB, et al. Trends in Melanoma Phase 3 Clinical Trials since 2010: Is there Hope for Advanced Melanoma Therapies beyond Approved Treatment Mechanisms? Cancers (Basel). MDPI. 2022;14:5184.","journal-title":"MDPI"},{"key":"3685_CR13","doi-asserted-by":"publisher","first-page":"1825","DOI":"10.1016\/j.ejca.2004.04.030","volume":"40","author":"AMM Eggermont","year":"2004","unstructured":"Eggermont AMM, Kirkwood JM. Re-evaluating the role of dacarbazine in metastatic melanoma: what have we learned in 30 years? Eur J Cancer Elsevier. 2004;40:1825\u201336.","journal-title":"Eur J Cancer Elsevier"},{"key":"3685_CR14","first-page":"1","volume":"6","author":"RJ Sullivan","year":"2018","unstructured":"Sullivan RJ, Atkins MB, Kirkwood JM, Agarwala SS, Clark JI, Ernstoff MS, et al. An update on the Society for Immunotherapy of Cancer consensus statement on tumor immunotherapy for the treatment of cutaneous melanoma: version 2.0. J Immunother cancer. Springer. 2018;6:1\u201323.","journal-title":"Springer"},{"key":"3685_CR15","doi-asserted-by":"publisher","first-page":"6393","DOI":"10.21873\/anticanres.12999","volume":"38","author":"K Mattila","year":"2018","unstructured":"Mattila K, Raanta P, Lahtela V, Pyrh\u00f6nen S, Koskivuo I, Vihinen P. Long-term survival of stage IV melanoma patients treated with BOLD combination chemotherapy and intermediate-dose subcutaneous interferon-alpha. Anticancer Res Int Inst Anticancer Res. 2018;38:6393\u20137.","journal-title":"Anticancer Res Int Inst Anticancer Res"},{"key":"3685_CR16","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1200\/JCO.2000.18.1.158","volume":"18","author":"MR Middleton","year":"2000","unstructured":"Middleton MR, Grob JJ, Aaronson N, Fierlbeck G, Tilgen W, Seiter S, et al. Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol Am Soc Clin Oncol. 2000;18:158.","journal-title":"J Clin Oncol Am Soc Clin Oncol"},{"key":"3685_CR17","doi-asserted-by":"publisher","first-page":"7892","DOI":"10.3390\/ijms21217892","volume":"21","author":"C-H Weng","year":"2020","unstructured":"Weng C-H, Wu C-S, Wu J-C, Kung M-L, Wu M-H, Tai M-H. Cisplatin-induced giant cells formation is involved in chemoresistance of melanoma cells. Int J Mol Sci MDPI. 2020;21:7892.","journal-title":"Int J Mol Sci MDPI"},{"key":"3685_CR18","doi-asserted-by":"publisher","first-page":"1942","DOI":"10.3390\/antiox10121942","volume":"10","author":"S Pizzimenti","year":"2021","unstructured":"Pizzimenti S, Ribero S, Cucci MA, Grattarola M, Monge C, Dianzani C, et al. Oxidative Stress-Related Mechanisms in Melanoma and in the Acquired Resistance to Targeted Therapies. Antioxid MDPI. 2021;10:1942.","journal-title":"Antioxid MDPI"},{"key":"3685_CR19","first-page":"259","volume":"8","author":"HA Tawbi","year":"2010","unstructured":"Tawbi HA, Buch SC. Chemotherapy resistance abrogation in metastatic melanoma. Clin Adv Hematol Oncol. 2010;8:259\u201366.","journal-title":"Clin Adv Hematol Oncol"},{"key":"3685_CR20","doi-asserted-by":"publisher","first-page":"3893","DOI":"10.2174\/092986712802002509","volume":"19","author":"S Mocellin","year":"2012","unstructured":"Mocellin S, Bertazza L, Benna C, Pilati P. Circumventing melanoma chemoresistance by targeting DNA repair. Curr Med Chem Bentham Sci Publishers. 2012;19:3893\u20139.","journal-title":"Curr Med Chem Bentham Sci Publishers"},{"key":"3685_CR21","doi-asserted-by":"crossref","unstructured":"Pham JP, Joshua AM, da Silva IP, Dummer R, Goldinger SM. Chemotherapy in cutaneous melanoma: is there still a role? Current Oncology Reports. 2023;25:609\u2013621.","DOI":"10.1007\/s11912-023-01385-6"},{"key":"3685_CR22","doi-asserted-by":"publisher","first-page":"5633","DOI":"10.2147\/CMAR.S263468","volume":"Taylor Francis","author":"S Hawthorne","year":"2020","unstructured":"Hawthorne S, Zhao L, Hanson M, Kanas G, Davis C, Robinson D, et al. Treatment of advanced\/metastatic melanoma in the United States and Western Europe: results of the CancerMPact survey. Cancer Manag Res. 2020;Taylor Francis:5633\u20139.","journal-title":"Cancer Manag Res"},{"key":"3685_CR23","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1186\/s13046-022-02489-w","volume":"41","author":"M Zarei","year":"2022","unstructured":"Zarei M, Hajihassani O, Hue JJ, Graor HJ, Loftus AW, Rathore M, et al. Wild-type IDH1 inhibition enhances chemotherapy response in melanoma. J Exp Clin Cancer Res. 2022;41:283.","journal-title":"J Exp Clin Cancer Res"},{"key":"3685_CR24","doi-asserted-by":"crossref","unstructured":"Dratkiewicz E, Simiczyjew A, Mazurkiewicz J, Zi\u0119tek M, Matkowski R, Nowak D. Hypoxia and extracellular acidification as drivers of melanoma progression and drug resistance. Cells. 2021;10:862","DOI":"10.3390\/cells10040862"},{"key":"3685_CR25","first-page":"68","volume":"7","author":"S Gupta","year":"2017","unstructured":"Gupta S, Roy A, Dwarakanath BS. Metabolic cooperation and competition in the tumor microenvironment: implications for therapy. Front Oncol Front. 2017;7:68.","journal-title":"Front Oncol Front"},{"key":"3685_CR26","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1111\/pcmr.12661","volume":"31","author":"GM Fischer","year":"2018","unstructured":"Fischer GM, Vashisht Gopal YN, McQuade JL, Peng W, DeBerardinis RJ, Davies MA. Metabolic strategies of melanoma cells: Mechanisms, interactions with the tumor microenvironment, and therapeutic implications. Pigment Cell Melanoma Res Wiley Online Libr. 2018;31:11\u201330.","journal-title":"Pigment Cell Melanoma Res Wiley Online Libr"},{"key":"3685_CR27","doi-asserted-by":"crossref","unstructured":"Jose C, Bellance N, Rossignol R. Choosing between glycolysis and oxidative phosphorylation: a tumor\u2019s dilemma? Biochim Biophys Acta Bioenerg. 2011;1807:552\u2013561.","DOI":"10.1016\/j.bbabio.2010.10.012"},{"key":"3685_CR28","first-page":"115","volume":"124","author":"PR Kumar","year":"2021","unstructured":"Kumar PR, Moore JA, Bowles KM, Rushworth SA, Moncrieff MD. Mitochondrial oxidative phosphorylation in cutaneous melanoma. Br J Cancer Nat Publishing Group. 2021;124:115\u201323.","journal-title":"Br J Cancer Nat Publishing Group"},{"key":"3685_CR29","first-page":"1","volume":"11","author":"I Mart\u00ednez-Reyes","year":"2020","unstructured":"Mart\u00ednez-Reyes I, Chandel NS. Mitochondrial TCA cycle metabolites control physiology and disease. Nat Commun Nat Publishing Group. 2020;11:1\u201311.","journal-title":"Nat Commun Nat Publishing Group"},{"key":"3685_CR30","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1016\/j.cell.2016.12.039","volume":"168","author":"MG Vander Heiden","year":"2017","unstructured":"Vander Heiden MG, DeBerardinis RJ. Understanding the intersections between metabolism and cancer biology. Cell Elsevier. 2017;168:657\u201369.","journal-title":"Cell Elsevier"},{"key":"3685_CR31","doi-asserted-by":"crossref","unstructured":"Nakazzi F, Zarei M, Lopes M, Graor HJ, Beegan WC, Gu E et al. Vitamin B3 derivatives support pancreatic cancer cell survival and chemotherapy resistance. Cancer Lett. 2026;218334. Available from: https:\/\/www.sciencedirect.com\/science\/article\/pii\/S0304383526000972.","DOI":"10.1016\/j.canlet.2026.218334"},{"key":"3685_CR32","doi-asserted-by":"publisher","first-page":"472","DOI":"10.3389\/fendo.2018.00472","volume":"9","author":"E Jaune","year":"2018","unstructured":"Jaune E, Rocchi S, Metformin. Focus on melanoma. Front Endocrinol (Lausanne) Front Media SA. 2018;9:472.","journal-title":"Front Endocrinol (Lausanne) Front Media SA"},{"key":"3685_CR33","first-page":"1","volume":"3","author":"G Blandino","year":"2012","unstructured":"Blandino G, Valerio M, Cioce M, Mori F, Casadei L, Pulito C, et al. Metformin elicits anticancer effects through the sequential modulation of DICER and c-MYC. Nat Commun Nat Publishing Group. 2012;3:1\u201311.","journal-title":"Nat Commun Nat Publishing Group"},{"key":"3685_CR34","first-page":"1","volume":"23","author":"MJ Bueno","year":"2021","unstructured":"Bueno MJ, Ruiz-Sepulveda JL, Quintela-Fandino M. Mitochondrial inhibition: a treatment strategy in cancer? Curr Oncol Rep Springer. 2021;23:1\u201311.","journal-title":"Curr Oncol Rep Springer"},{"key":"3685_CR35","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/nchembio.1712","volume":"11","author":"SE Weinberg","year":"2015","unstructured":"Weinberg SE, Chandel NS. Targeting mitochondria metabolism for cancer therapy. Nat Chem Biol Nat Publishing Group. 2015;11:9\u201315.","journal-title":"Nat Chem Biol Nat Publishing Group"},{"key":"3685_CR36","doi-asserted-by":"publisher","first-page":"18226","DOI":"10.1073\/pnas.1317577110","volume":"110","author":"P Yuan","year":"2013","unstructured":"Yuan P, Ito K, Perez-Lorenzo R, Del Guzzo C, Lee JH, Shen C-H, et al. Phenformin enhances the therapeutic benefit of BRAFV600E inhibition in melanoma. Proc Natl Acad Sci Natl Acad Sci. 2013;110:18226\u201331.","journal-title":"Proc Natl Acad Sci Natl Acad Sci"},{"key":"3685_CR37","doi-asserted-by":"publisher","first-page":"1719","DOI":"10.1002\/1878-0261.13583","volume":"18","author":"M Pujalte-Martin","year":"2024","unstructured":"Pujalte-Martin M, Bela\u00efd A, Bost S, Kahi M, Peraldi P, Rouleau M, et al. Targeting cancer and immune cell metabolism with the complex I inhibitors metformin and IACS\u2010010759. Mol Oncol Wiley Online Libr. 2024;18:1719\u201338.","journal-title":"Mol Oncol Wiley Online Libr"},{"key":"3685_CR38","doi-asserted-by":"crossref","unstructured":"Zarei M, Hajihassani O, Hue JJ, Loftus AW, Graor HJ, Nakazzi F, et al. IDH1 inhibition potentiates chemotherapy efficacy in pancreatic cancer. Cancer Res. 2024;84:3072\u20133085.","DOI":"10.1158\/0008-5472.CAN-23-1895"},{"key":"3685_CR39","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1158\/2767-9764.CRC-21-0073","volume":"1","author":"M Zarei","year":"2021","unstructured":"Zarei M, Shrestha R, Johnson S, Yu Z, Karki K, Vaziri-Gohar A, et al. Nuclear Receptor 4A2 (NR4A2\/NURR1) Regulates Autophagy and Chemoresistance in Pancreatic Ductal Adenocarcinoma. Cancer Res Commun AACR. 2021;1:65\u201378.","journal-title":"Cancer Res Commun AACR"},{"key":"3685_CR40","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1080\/19466315.2018.1437071","volume":"10","author":"Q Liu","year":"2018","unstructured":"Liu Q, Yin X, Languino LR, Altieri DC. Evaluation of drug combination effect using a bliss independence dose\u2013response surface model. Stat Biopharm Res Taylor Francis. 2018;10:112\u201322.","journal-title":"Stat Biopharm Res Taylor Francis"},{"key":"3685_CR41","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1038\/nprot.2012.024","volume":"7","author":"M Yuan","year":"2012","unstructured":"Yuan M, Breitkopf SB, Yang X, Asara JM. A positive\/negative ion\u2013switching, targeted mass spectrometry\u2013based metabolomics platform for bodily fluids, cells, and fresh and fixed tissue. Nat Protoc Nat Publishing Group. 2012;7:872\u201381.","journal-title":"Nat Protoc Nat Publishing Group"},{"key":"3685_CR42","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.molmed.2014.12.007","volume":"21","author":"C Abildgaard","year":"2015","unstructured":"Abildgaard C, Guldberg P. Molecular drivers of cellular metabolic reprogramming in melanoma. Trends Mol Med Elsevier. 2015;21:164\u201371.","journal-title":"Trends Mol Med Elsevier"},{"key":"3685_CR43","doi-asserted-by":"crossref","unstructured":"Kalal BS, Upadhya D, Pai VR. Chemotherapy resistance mechanisms in advanced skin cancer. Oncol Rev. 2017;11:326.","DOI":"10.4081\/oncol.2017.326"},{"key":"3685_CR44","doi-asserted-by":"publisher","first-page":"3197","DOI":"10.3390\/cells10113197","volume":"10","author":"C Huang","year":"2021","unstructured":"Huang C, Radi RH, Arbiser JL. Mitochondrial metabolism in melanoma. Cells MDPI. 2021;10:3197.","journal-title":"Cells MDPI"},{"key":"3685_CR45","doi-asserted-by":"publisher","first-page":"855782","DOI":"10.3389\/fonc.2022.855782","volume":"12","author":"EM Gaughan","year":"2022","unstructured":"Gaughan EM, Horton BJ. Outcomes from cytotoxic chemotherapy following progression on immunotherapy in metastatic melanoma: an institutional case-series. Front Oncol. 2022;12:855782.","journal-title":"Front Oncol"},{"key":"3685_CR46","doi-asserted-by":"crossref","unstructured":"Campagna R, Bacchetti T, Salvolini E, Pozzi V, Molinelli E, Brisigotti V, et al. Paraoxonase-2 silencing enhances sensitivity of A375 melanoma cells to treatment with cisplatin. Antioxidants. Volume 9. Multidisciplinary Digital Publishing Institute; 2020. p. 1238.","DOI":"10.3390\/antiox9121238"},{"key":"3685_CR47","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1016\/j.redox.2017.01.010","volume":"11","author":"AK-W Tse","year":"2017","unstructured":"Tse AK-W, Chen Y-J, Fu X-Q, Su T, Li T, Guo H, et al. Sensitization of melanoma cells to alkylating agent-induced DNA damage and cell death via orchestrating oxidative stress and IKK\u03b2 inhibition. Redox Biol Elsevier. 2017;11:562\u201376.","journal-title":"Redox Biol Elsevier"},{"key":"3685_CR48","doi-asserted-by":"crossref","unstructured":"Shelton SD, House S, Martins Nascentes Melo L, Ramesh V, Chen Z, Wei T, et al. Pathogenic mitochondrial DNA mutations inhibit melanoma metastasis. Sci Adv. 2024;10:eadk8801.","DOI":"10.1126\/sciadv.adk8801"},{"key":"3685_CR49","first-page":"1","volume":"3","author":"L Sch\u00f6ckel","year":"2015","unstructured":"Sch\u00f6ckel L, Glasauer A, Basit F, Bitschar K, Truong H, Erdmann G, et al. Targeting mitochondrial complex I using BAY 87-2243 reduces melanoma tumor growth. Cancer Metab Springer. 2015;3:1\u201316.","journal-title":"Cancer Metab Springer"},{"key":"3685_CR50","doi-asserted-by":"publisher","first-page":"2482","DOI":"10.1158\/1078-0432.CCR-17-3070","volume":"24","author":"TM Ashton","year":"2018","unstructured":"Ashton TM, McKenna WG, Kunz-Schughart LA, Higgins GS. Oxidative phosphorylation as an emerging target in cancer therapy. Clin Cancer Res AACR. 2018;24:2482\u201390.","journal-title":"Clin Cancer Res AACR"},{"key":"3685_CR51","first-page":"1036","volume-title":"An inhibitor of oxidative phosphorylation exploits cancer vulnerability. Nat Med","author":"JR Molina","year":"2018","unstructured":"Molina JR, Sun Y, Protopopova M, Gera S, Bandi M, Bristow C, et al. An inhibitor of oxidative phosphorylation exploits cancer vulnerability. Nat Med. Volume 24. New York: Nature Publishing Group US; 2018. pp. 1036\u201346."},{"key":"3685_CR52","first-page":"e02242","volume":"3","author":"WW Wheaton","year":"2014","unstructured":"Wheaton WW, Weinberg SE, Hamanaka RB, Soberanes S, Sullivan LB, Anso E, et al. Metformin inhibits mitochondrial complex I of cancer cells to reduce tumorigenesis. Elife eLife Sci Publications Ltd. 2014;3:e02242.","journal-title":"Elife eLife Sci Publications Ltd"},{"key":"3685_CR53","doi-asserted-by":"publisher","first-page":"2447","DOI":"10.1158\/2767-9764.CRC-23-0296","volume":"3","author":"PB Chapman","year":"2023","unstructured":"Chapman PB, Klang M, Postow MA, Shoushtari AN, Sullivan RJ, Wolchok JD, et al. Phase Ib trial of phenformin in patients with V600-mutated melanoma receiving dabrafenib and trametinib. Cancer Res Commun Am Association Cancer Res. 2023;3:2447\u201354.","journal-title":"Cancer Res Commun Am Association Cancer Res"}],"container-title":["Journal of Experimental &amp; Clinical Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13046-026-03685-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-026-03685-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-026-03685-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T20:52:34Z","timestamp":1781643154000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13046-026-03685-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,26]]},"references-count":53,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["3685"],"URL":"https:\/\/doi.org\/10.1186\/s13046-026-03685-8","relation":{},"ISSN":["1756-9966"],"issn-type":[{"value":"1756-9966","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,26]]},"assertion":[{"value":"12 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"109"}}